Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature

Ventilator-associated pneumonia (VAP) in critically ill patients with COVID-19 represents a very huge global threat due to a higher incidence rate compared to non-COVID-19 patients and almost 50% of the 30-day mortality rate. <i>Pseudomonas aeruginosa</i> was the first pathogen involved...

Full description

Bibliographic Details
Main Authors: Giulia Jole Burastero, Gabriella Orlando, Antonella Santoro, Marianna Menozzi, Erica Franceschini, Andrea Bedini, Adriana Cervo, Matteo Faltoni, Erica Bacca, Emanuela Biagioni, Irene Coloretti, Gabriele Melegari, Jessica Maccieri, Stefano Busani, Elisabetta Bertellini, Massimo Girardis, Giulia Ferrarini, Laura Rofrano, Mario Sarti, Cristina Mussini, Marianna Meschiari
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Antibiotics
Subjects:
non-fermenter gram negative
VAP
ceftazidime/avibactam
Online Access:https://www.mdpi.com/2079-6382/11/8/1007

Internet

https://www.mdpi.com/2079-6382/11/8/1007

Similar Items